Bringing Blood-Based Molecular Testing to the Clinic.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27663595.
- Also identified by DOI 10.1158/1078-0432.CCR-16-1769.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In cancer, plasma-derived cell-free DNA can be used for detection of oncogenic aberrations relevant for treatment selection. A cell-free DNA-based test for EGFR mutations has been approved as an alternative to tumor tissue analysis in lung cancer. Testing for other aberrations, including copy number alterations, continues to be investigated. Clin Cancer Res; 22(22); 5400-2. ©2016 AACRSee related article by Chicard et al., p. 5564.
Medical subject headings
- DNA, Neoplasm
- Lung Neoplasms